
There’s no downplaying how lucrative the weight-loss drug industry is.
Novo Nordisk, the Danish pharma giant, has seen its fortunes reach astronomical heights since its drugs, Ozempic and Wegovy, took off. Its shares have risen 432% in the last five years, and the company’s market cap far exceeds the size of Denmark’s economy—catapulted by the success of the weight-shedding injections.